DGIdb - PANITUMUMAB Drug Record

PANITUMUMAB EREG

Interaction Score: 4.42

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26867820

Sources:
CIViC PharmGKB
PANITUMUMAB BRAF

Interaction Score: 2.97

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Panitumumab + Dabrafenib + Trametinib

combination therapy Vemurafenib + Panitumumab

Clinical Status late trials

PMIDs:
23325582 21163703 20619739 28783719 25673644 29431699 26687137 19001320 22038996 19773371 23845441 14679157 22180495 21156289 21663470 22356324 12460918 18541894 23406027 21129611 22536370 23470635 23251002 24594804 19018267 22586120 24388723 19010912 24508103 20857202 19537845 21975775 26678033 22448344 25024077 20350999 24163374 19561230 19255327 23031422 22351686 22048237 23833300 24576830 22389471 23020132 22997239 19238210 23524406 22735384 22281684 19404918 25370471 24570209 23612012 20630094 23489023 21426297 21639808 20413299 23812671 23614898 22649091 22972589 24396464 24583796 20368568 24107445 22241789 26619011 24586605 23918947 24354346 21594703 15035987 22663011 23549875 21683865 22805292 23934108 25157968 25989278 20818844 22773810 22608338 21483012 12460919 22743296 12068308 27770002 27312529 28514312 25589621 31515458

Sources:
JAX-CKB DoCM CIViC OncoKB
PANITUMUMAB AREG

Interaction Score: 2.36

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26867820 23959273

Sources:
CIViC PharmGKB
PANITUMUMAB BTC

Interaction Score: 1.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PANITUMUMAB NRG2

Interaction Score: 1.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PANITUMUMAB TGFA

Interaction Score: 1.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PANITUMUMAB KRAS

Interaction Score: 1.26

Interaction Types & Directionality:

n/a

Interaction Info:

Variant Effect gain-of-function

Pathway activation

Clinical Status FDA-rejected

PMIDs:
20978259 3122217 21398618 19679400 18316791 19075190 23182985 21975775 26812186 19018267 23406027 22734028 19114683 16618717 25157968 21228335 17384584 19255327 26371285 20921462 18794081 16434492 19773371 22392911 16361624 26623049 22407852 24558511 20921465 12460918 2278970 28404754 26540314 23625191 24919569 19064407 26341920 28275037 19223544 27897268 26438111 26162609 25210463 25183481 24727325 23324806 23090619 23071293 22537608 23404247 26644315

Sources:
ClearityFoundationBiomarkers JAX-CKB DoCM CIViC PharmGKB OncoKB
PANITUMUMAB EGF

Interaction Score: 0.98

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PANITUMUMAB HBEGF

Interaction Score: 0.98

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PANITUMUMAB NRG3

Interaction Score: 0.98

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PANITUMUMAB EGFR

Interaction Score: 0.81

Interaction Types & Directionality:

suppressor (inhibitory)

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor

Direct Interaction yes

Novel drug target Established target

PMIDs:
22270724 11894013 16857825 11255078 20481659 18343240 18503402 14967460 17355997 20623992 11752352 16012181 12620146 23959273 23022519 22594511 19339720 18784101 18681783 18316547 18003960 16467544 16377102 16257339 14990633 14990632 12648464 27312529 17664472 26843189 26888827 24653627 28287083 29196463

Sources:
TALC ClearityFoundationBiomarkers MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions TEND DoCM CIViC PharmGKB TTD FDA
PANITUMUMAB NRAS

Interaction Score: 0.63

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal cancer

Response Type predicted – sensitive

Approval Status Phase III

PMIDs:
23325582 20619739 24024839 26438111 28275037 26341920

Sources:
JAX-CKB CIViC PharmGKB OncoKB
PANITUMUMAB CDKN2A

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23746666

Sources:
CIViC
PANITUMUMAB MAP2K1

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Panitumumab + Trametinib

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
26644315 31227518

Sources:
JAX-CKB CIViC
PANITUMUMAB HRAS

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type resistant

Approval Status Preclinical

PMIDs:
22797062

Sources:
JAX-CKB
PANITUMUMAB NRG1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PANITUMUMAB PTEN

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19223544

Sources:
ClearityFoundationBiomarkers CIViC
PANITUMUMAB MET

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy JNJ 38877605 + Panitumumab

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
23729478

Sources:
JAX-CKB
PANITUMUMAB PIK3CA

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19223544

Sources:
CIViC
PANITUMUMAB ERBB2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal cancer

Response Type resistant

Approval Status Preclinical

PMIDs:
26243863

Sources:
JAX-CKB
PANITUMUMAB TP53

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Vemurafenib + Panitumumab

Indication/Tumor Type colon cancer

Response Type sensitive

PMIDs:
28514312

Sources:
JAX-CKB

FDA Approval	approved
Drug Class	monoclonal antibody
Drug Indications	antineoplastic agent
Year of Approval	2006
Drug Class	antineoplastic agents
FDA Approval	Colorectal cancer (KRAS wild type)
Drug Class	Therapeutic Antibodies

Drug Class	antineoplastic agents
Year of Approval	2006

ABX-EGF	Development Name
PANITUMUMAB	Generic Name
VECTIBIX	Trade Name

Drug Class	Therapeutic Antibodies
FDA Approval	Colorectal cancer (KRAS wild type)

Drug Indications	antineoplastic agent
Drug Class	monoclonal antibody
FDA Approval	approved

combination therapy	Panitumumab + Dabrafenib + Trametinib
combination therapy	Vemurafenib + Panitumumab
Clinical Status	late trials

Variant Effect	gain-of-function
Pathway	activation
Clinical Status	FDA-rejected

Mechanism of Interaction	Epidermal growth factor receptor erbB1 inhibitor
Direct Interaction	yes
Novel drug target	Established target

Indication/Tumor Type	colorectal cancer
Response Type	predicted – sensitive
Approval Status	Phase III

combination therapy	Panitumumab + Trametinib
Indication/Tumor Type	colorectal cancer
Response Type	sensitive

Indication/Tumor Type	Advanced Solid Tumor
Response Type	resistant
Approval Status	Preclinical

combination therapy	JNJ 38877605 + Panitumumab
Indication/Tumor Type	colorectal cancer
Response Type	sensitive

PANITUMUMAB	Primary Drug Name
PANITUMUMAB	Drug Generic Name
VECTIBIX	Drug Trade Name

PANITUMUMAB
E7.6.3
L01XC08
ABX-EGF
VECTIBIX
chemidplus:339177-26-3
drugbank:01269
chembl:CHEMBL1201827
rxcui:263034

suppressor (inhibitory)
antibody (inhibitory)
inhibitor (inhibitory)

PANITUMUMAB Drug Record

PANITUMUMAB chembl:CHEMBL1201827 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26867820

Sources: CIViC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Panitumumab + Dabrafenib + Trametinib combination therapy Vemurafenib + Panitumumab Clinical Status late trials

Sources: JAX-CKB DoCM CIViC OncoKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26867820 23959273

Sources: CIViC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: Variant Effect gain-of-function Pathway activation Clinical Status FDA-rejected

Sources: ClearityFoundationBiomarkers JAX-CKB DoCM CIViC PharmGKB OncoKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: suppressor (inhibitory) antibody (inhibitory) inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor Direct Interaction yes Novel drug target Established target

Sources: TALC ClearityFoundationBiomarkers MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions TEND DoCM CIViC PharmGKB TTD FDA

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type colorectal cancer Response Type predicted – sensitive Approval Status Phase III

PMIDs: 23325582 20619739 24024839 26438111 28275037 26341920

Sources: JAX-CKB CIViC PharmGKB OncoKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23746666

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Panitumumab + Trametinib Indication/Tumor Type colorectal cancer Response Type sensitive

PMIDs: 26644315 31227518

Sources: JAX-CKB CIViC

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type Advanced Solid Tumor Response Type resistant Approval Status Preclinical

PMIDs: 22797062

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19223544

Sources: ClearityFoundationBiomarkers CIViC

Interaction Types & Directionality: n/a

Interaction Info: combination therapy JNJ 38877605 + Panitumumab Indication/Tumor Type colorectal cancer Response Type sensitive

PMIDs: 23729478

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19223544

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type colorectal cancer Response Type resistant Approval Status Preclinical

Interaction Types & Directionality:

n/a

PMIDs:
26867820

Sources:
CIViC PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Panitumumab + Dabrafenib + Trametinib

combination therapy Vemurafenib + Panitumumab

Clinical Status late trials

Sources:
JAX-CKB DoCM CIViC OncoKB

Interaction Types & Directionality:

n/a

PMIDs:
26867820 23959273

Sources:
CIViC PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Variant Effect gain-of-function

Pathway activation

Clinical Status FDA-rejected

Sources:
ClearityFoundationBiomarkers JAX-CKB DoCM CIViC PharmGKB OncoKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

suppressor (inhibitory)

antibody (inhibitory)

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Epidermal growth factor receptor erbB1 inhibitor

Direct Interaction yes

Novel drug target Established target

Sources:
TALC ClearityFoundationBiomarkers MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions TEND DoCM CIViC PharmGKB TTD FDA

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal cancer

Response Type predicted – sensitive

Approval Status Phase III

PMIDs:
23325582 20619739 24024839 26438111 28275037 26341920

Sources:
JAX-CKB CIViC PharmGKB OncoKB

Interaction Types & Directionality:

n/a

PMIDs:
23746666

Sources:
CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Panitumumab + Trametinib

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
26644315 31227518

Sources:
JAX-CKB CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type resistant

Approval Status Preclinical

PMIDs:
22797062

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
19223544

Sources:
ClearityFoundationBiomarkers CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy JNJ 38877605 + Panitumumab

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
23729478

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
19223544

Sources:
CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal cancer

Response Type resistant

Approval Status Preclinical

PMIDs:
26243863

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Vemurafenib + Panitumumab

Indication/Tumor Type colon cancer

Response Type sensitive

PMIDs:
28514312

Sources:
JAX-CKB

Alternate Names:

PANITUMUMAB Primary Drug Name

Drug Info:

Drug Class antineoplastic agents

Year of Approval 2006

Alternate Names:

ABX-EGF Development Name

PANITUMUMAB Generic Name

VECTIBIX Trade Name

Drug Info:

Drug Class Therapeutic Antibodies

FDA Approval Colorectal cancer (KRAS wild type)

Drug Info:

Drug Indications antineoplastic agent

Drug Class monoclonal antibody

FDA Approval approved

Alternate Names:

PANITUMUMAB Primary Drug Name

PANITUMUMAB Drug Generic Name

VECTIBIX Drug Trade Name

Alternate Names:

D0HU9H TTD Drug ID

Alternate Names:

D0P9RG TTD Drug ID